MatchMiner-AI: An Open-Source Solution for Cancer Clinical Trial Matching

Ethan Cerami, PhD; Pavel Trukhanov, MSc; Morgan A. Paul, MB; Michael J. Hassett, MD, MPH; Irbaz B. Riaz, MD PhD; James Lindsay, PhD; Emily Mallaber, BA; Harry Klein, PhD; Gufran Gungor, BS; Matthew Galvin, BS; Stephen C. Van Nostrand, MS; Joyce Yu, MBA; Tali Mazor, PhD; Kenneth L. Kehl, MD, MPH

Affiliations:Dana-Farber Cancer Institute (EC, PT, MAB, MJH,JL, EM, HK, GG, MG, SCVN, JY, KLK); Mayo Clinic (IR)

Version 1.0.0

Abstract

Clinical trials drive improvements in cancer treatments and outcomes. However, most adults with cancer do not participate in trials, and trials often fail to enroll enough patients to answer their scientific questions. Artificial intelligence could accelerate matching of patients to appropriate clinical trials. Here, we describe the development and evaluation of the MatchMiner-AI pipeline for clinical trial searching and ranking. MatchMiner-AI focuses on matching patients to potential trials based on core criteria describing clinical "spaces," or disease contexts, targeted by a trial. It aims to accelerate the human work of identifying potential matches, not to fully automate trial screening. The pipeline includes modules for extraction of key information from a patient's longitudinal electronic health record; rapid ranking of candidate trial-patient matches based on embeddings in vector space; and classification of whether a candidate match represents a reasonable clinical consideration. Code and synthetic data are available at https://huggingface.co/ksg-dfci/MatchMiner-AI . Model weights based on synthetic data are available at https://huggingface.co/ksg-dfci/TrialSpace and <a hre

https://huggingface.co/spaces/ksg-dfci/trial_search_alpha .

Introduction

Clinical trials are critical to developing new cancer treatments and improving patient outcomes. Historically, however, less than 10% of adults with cancer have participated in clinical trials.¹ At the same time, many trials fail to reach their accrual goals.^{2,3} A need has therefore arisen for methods that can match patients to clinical trials at scale.

Several such tools have been developed. For example, genomic testing labs^{4,5} provide clinical trial options based on genomic eligibility criteria. Patient-facing products that allow informed patients to enter their own histories and receive a list of trial options have been created.^{6–8} Companies offer proprietary algorithms to cancer centers to facilitate trial feasibility assessment and patient matching.⁹ Machine learning or "artificial intelligence" approaches to match patients to clinical trials have also been created.^{10–12} Most recently, efforts have been undertaken to apply large language models (LLMs) to unstructured clinical data for clinical trial matching. This has included applying LLMs for the explicit extraction of structured variables from patient records, ^{13–15} often focused on individual clinical notes, and explicit extraction of structured approaches to privacy-aware data augmentation for clinical trials,¹⁷ published end-to-end LLM-based trial matching systems,^{18,19} and investigated the computational and cost efficiencies of various LLM approaches to trial matching.²⁰

Still, most of these tools attempt to extract all eligibility criteria for a trial and evaluate if a patient matches each one. This comprehensive approach is intuitive, but given the complexity of eligibility criteria for modern cancer trials, it may risk limiting the feasibility and utility of automated trial-matching tools. Some eligibility criteria, such as blood count values and kidney or liver function test results, are common to almost any clinical trial. Matching on these criteria therefore does little to assist with ranking specific trials for a given patient who is eligible for trials in general. Focusing instead on matching based on core criteria for individual trials – such

Page 3

as cancer type/histology, disease context (localized disease/curative intent vs advanced/metastatic), prior treatment history, and key biomarkers – may be useful. Each combination of such core criteria could be defined as a clinical "space," representing a target population for which a drug is being developed. Some trials encapsulate only one such space, such as "Previously untreated metastatic lung adenocarcinoma with an activating EGFR mutation." Others, such as basket trials,²¹ may be open to patients in several clinical spaces.

In this manuscript, we describe the development and validation of the open-source MatchMiner-AI pipeline. MatchMiner-AI ranks cancer clinical trial options for patients, and patients for clinical trials, based on unstructured EHR data and trial documentation. Key components of the pipeline include leveraging a large language model (LLM) to (1) define the core clinical criteria that define target patient populations, or "spaces," for each trial; (2) summarize longitudinal clinical patient data based on EHR documents; (3) fine-tune a "TrialSpace" text embedding model based on historical enrollment data; and (4) train a "TrialChecker" classification model to predict whether a given candidate patient meets the core eligibility criteria for a specific clinical trial.

Methods

Core Clinical Criteria and Clinical Trial Spaces

The Dana-Farber Havard Cancer Center clinical trial database was queried to identify all therapeutic clinical trials open to accrual at DFCI from January 2012 to June 2024. The NCT IDs for these trials were used to download publicly available eligibility criteria for each trial from the clinicaltrials.gov API. Llama-3.1-70B²² was prompted to extract lists of target "spaces" for each trial (Supplementary Table 1). The prompt defined a "space" as an individual combination of cancer type/histology, disease burden/intent of treatment (curative or advanced/metastatic),

prior treatment history, and biomarker requirements that constituted a phenotype eligible for the trial. Some trials have only one target space, whereas others have several. The space list for each trial was parsed to extract the text describing each individual target clinical space.

Patient cohorts

EHR data were obtained using the DFCI Oncology Data Retrieval System²³ for all adults who enrolled in cancer treatment clinical trials at DFCI from January 2016 to April 2024. These data included unstructured clinical notes, imaging reports, and pathology reports; and all structured systemic therapy treatment plans, including clinical trial enrollment details; stored in the shared Mass General Brigham-DFCI legacy EHR (pre-2015) or Epic EHR (since 2015). Data were split, at the patient level, into training (80%), validation/tuning (10%), and test (10%) subsets.

Access to data for this study was approved by the Dana/Farber Harvard Cancer Center Institutional Review Board (Protocol #21-608). Given the large volume of data required and minimal risk to patients of this retrospective medical records analysis study, a waiver of informed consent was obtained.

Pipeline development

Our pipeline consisted of a multistep model training and deployment process, as described below and illustrated in **Figure 1**.

1. Condensing the medical record

Many patients with cancer have long clinical histories, which can exceed the context length limitations of even long-context LLMs. Retrieval-augmented generation (RAG) is a common approach to pulling information from relevant documents or excerpts of text using vector embeddings to augment a prompt to an LLM, improving the quality of its responses while remaining within context length limits.²⁴ In preliminary work, however, we found that applying the RAG concept using off-the-shelf embedding models to extract phenotypically relevant text from a medical record sometimes missed important information, partly due to the duplicative nature of much of the information in an EHR.

Therefore, we developed a custom model for condensing a patient's medical record to the most relevant information. For each patient who enrolled on a therapeutic trial in our retrospective datasets, all unstructured oncologist notes, imaging reports, and pathology reports were pulled from the EHR. For a sample of 10,000 such patients from the training and validation sets (89% training, 11% validation), Llama 3.1-70B was prompted to tag each sentence in the medical record according to whether the sentence was relevant to a list of target concepts, including cancer type, histology, stage of diagnosis, current extent of disease, treatment history, and biomarkers. A multitask classification model based on TinyBERT²⁵ was then trained on a per-sentence basis to predict whether any tag was assigned by Llama and which tags were evaluated on the validation set. The model was then applied to each sentence in the medical records for all patients who had enrolled on trials in our dataset, and the sentences exceeding the best F1 threshold for predicting a Llama tag were retained and concatenated chronologically to create a single condensed medical record for each patient.

2. Patient summarization

Using the condensed medical record, Llama-3.1-70B was then prompted to summarize each patient's history through the time the patient enrolled on a clinical trial. The patient summarization prompt to Llama (Supplementary Table 1) instructed the LLM to generate semi-structured output capturing the same core clinical concepts used to define trial spaces, including cancer type/histology, disease context (localized disease/curative intent vs advanced/metastatic), prior treatment history, and key biomarkers. See Figure 2 for an example of patient summaries.

3. Trial space extraction

For each therapeutic clinical trial with enrollments in our dataset, eligibility criteria text was pulled from the clinicaltrials.gov Application Programming Interface (API). For each trial, Llama-3.1-70B was prompted to extract a list of semi-structured clinical spaces that matched the trial, where each space was defined as above as a unique combination of core clinical concepts (Supplementary Table 1). See Figure 2 for an example of a trial space.

4. TrialSpace model development

Initial TrialSpace training

Next, retrospective possible patient-space combinations were defined by linking each free-text patient summary from the time the patient enrolled on a given trial to each of the free-text clinical spaces extracted for that trial. Since we knew the trial on which each patient enrolled, but we did not have information a priori regarding the specific space for the trial on which the patient enrolled, we prompted Llama-3.1-70B to evaluate whether each trial space was a "reasonable consideration" based on the patient summary. The prompt (Supplementary Table)

instructed Llama to first reason about whether the patient matched the core clinical criteria; and then to generate a summary "yes" or "no" answer.

Then, a text embedding model was trained to embed well-matched patient summaries and trial spaces. First, the stella-en-1.5B v5²⁶ text embedding model was fine-tuned simultaneously on two tasks: (1) using the multiple negatives ranking loss²⁷ to discriminate between true patient-space combinations that passed the "reasonable considerations" per the Llama prompt above and random patient-space combinations; and (2) using the online contrastive loss to place patient-space combinations that passed the Llama check closer together than those that did not.

TrialSpace refinement

We empirically found that the initial TrialSpace training step yielded a model that could identify clinical trials based on cancer type but did not discriminate as well within cancer types according to specific treatment history or biomarker criteria. Therefore, we fine-tuned TrialSpace further to improve performance at discriminating among trial spaces or patients that might otherwise be highly ranked matches but were not "reasonable considerations" per Llama-3.1-70B. We used the preliminary TrialSpace model to identify the ten trial spaces that best matched each patient summary and the twenty patient summaries that best matched each trial space based on the cosine similarity metric. Llama-3.1-70B was again prompted to determine whether each of these top ten spaces was a "reasonable consideration" given the patient summary, and whether each of the top twenty patients was a reasonable consideration for a trial space, yielding an intermediate dataset containing binary labels for each patient-space combination. We then fine-tuned the embedding model further on the dual tasks of (1) discriminating between matches that passed a Llama 'reasonable consideration' check and random patient-space matches, again using the multiple negatives ranking loss; and (2) predicting the binary Llama "reasonable

consideration" label given a candidate patient summary and one of the top ten ranked spaces for that summary, or a candidate space and one of the top twenty ranked patients for that space, using the online contrastive loss. Candidate patient-trial space matches were restricted to spaces derived from trials that were open to accrual at the time the patient enrolled in a trial.

TrialSpace evaluation

Successive iterations of TrialSpace were evaluated in the retrospective validation set as follows. The top-10 precision of the patient-centric/"trial spaces for patients" pipeline for predicting the Llama reasonable consideration label, and the top 20 precision of the trial-centric/"patients for trial spaces" pipeline for predicting that label, were calculated. The mean average precision (MAP) at 10 for the "trial spaces for patients" use case and at 20 for the "patients for trial spaces" use case were also measured. Candidate patient-space matches were restricted to those spaces derived from trials that were open when the patient enrolled in any trial. To aid intuitive interpretation of TrialSpace embeddings, we also applied Uniform Manifold Approximation and Projection (UMAP)²⁸ to perform dimensionality reduction and visualize a projection of the embedding space into two dimensions by cancer type. Once models were finalized, the precision metrics for the patient-centric workflow were evaluated in the held-out patient test split. The precision for the trial-centric workflow was performed using all patient splits, since data were split at the patient rather than the trial level, and trials were therefore not held out from training in the same way that patients were.

5. TrialChecker model development and validation

The TrialSpace model enables pre-calculation of embedding vectors for patient summaries and trial spaces, so subsequent queries of each can be performed almost instantly without requiring

inference on each possible combination of patient and trial space.²⁹ However, the quality of rankings provided by TrialSpace necessarily depends on the number of trial spaces and patients available for matching, since more options will increase the probability that each of the top ranked options for a given query is a reasonable consideration. Furthermore, the cosine similarity between patient and trial space vectors is not a clinically intuitive metric to present to oncologists and trial investigators.

Therefore, we trained a "TrialChecker" classification model to generate a predicted probability that a specific patient-trial space combination would be deemed a reasonable consideration by the Llama-3.1-70B prompt. TrialChecker can be applied just to the top ranked matches to a given patient or trial space query, increasing the specificity of matches presented to the user. We fine-tuned this model from a Roberta-Large base³⁰ using the Huggingface³¹ library. TrialChecker can be run in real time to "double-check" the top ten ranked spaces for a given patient or top twenty patients for a given space. The training data for TrialChecker consisted of the training split subsets of (a) our retrospective enrollment dataset from the first step of TrialSpace training, linking patient summaries to each space corresponding to a trial on which the patient actually enrolled; plus (b) the top 10 space/top 20 patient dataset used to fine-tune the final TrialSpace model based on the retrospective enrollment dataset; and (c) a top 10 space/top 20 patient dataset generated by applying the final TrialSpace model. For each patient-space combination, Llama-3.1-70B was gueried to ascertain whether the space was a reasonable clinical consideration for the patient, yielding a binary outcome variable for TrialChecker training. The trained TrialChecker model was then evaluated by calculating the AUROC and calibration on the validation split subsets of datasets (a)-(c).

6. Full pipeline evaluation in retrospective DFCI enrollment data

We anticipated that users of these tools prospectively would likely use it to identify (1) the most relevant trial spaces for individual patients (a patient-centric use case), or (2) the most relevant patients for individual trial spaces (a trial-centric use case). The full pipeline – consisting of condensing the medical record for a patient, summarizing it, embedding patient summaries and trial spaces with TrialSpace, ranking top spaces for patients or top patients for spaces, and restricting to candidate patient-space matches predicted to be "reasonable clinical considerations" by TrialChecker – was then evaluated for both use cases. The overall precision and mean average precision of the pipeline were calculated, with and without the TrialChecker step. The performance of TrialChecker at predicting the Llama "reasonable consideration" response was measured using the area under the receiver operating characteristic curve (AUROC), area under the precision-recall curve (AUPRC), and calibration curves.

7. Evaluation beyond clinical trial enrollees at our center

To better understand the performance of the pipeline beyond our retrospective trial enrollment dataset, we identified patients at DFCI who started standard of care systemic therapies from 2016-2024. These patients were divided into 80% training, 10% validation, and 10% test sets, maintaining consistency with the trial enrollment dataset, so any patients in both the trial enrollment and the standard of care dataset were assigned to the same split in each. Patient summaries at the treatment start time points were then generated by the pipeline, and summaries were restricted to those for test set patients. Next, we downloaded eligibility criteria for all trials in clinicaltrials.gov that were open for a diagnosis of "cancer" as of October 22, 2024. A random sample of 500 such trials was selected, to reflect a volume of open trials consistent with historical DFCI trends. TrialSpace was used to identify the top 10 spaces for each patient and top 20 patients for each space. The performance of TrialChecker in the

resulting dataset was evaluated using the AUROC and calibration curves, and TrialChecker was then applied to restrict each candidate match list to those matches predicted to pass the Llama "reasonable consideration" check. The performance of the pipeline was evaluated by calculating the overall precision and mean average precision of the trial-space candidate matches, treating the Llama reasonable consideration check as a gold standard label, with and without filtering for matches that passed the TrialChecker filter.

8. Trialspace visualization

To provide a visual representation of TrialSpace vectors, the embeddings of both patient and trial space summaries were projected into two dimensions using the uniform manifold approximation and projection (UMAP) algorithm²⁸, which is an unsupervised dimensionality reduction technique that preserves the global structure of high-dimensional data. Every patient summary was processed to identify the cancer type (top-level OncoTree diagnosis code³²) by prompting Llama-3.1-70B (prompt described in Supplementary Table 1). All patients from the retrospective trial enrollment test dataset and all patients in the standard of care treatment test set were analyzed; however, any patient summaries for which the cancer type prompt did not return an Oncotree-compliant value were discarded from the visualization. A k-nearest neighbors analysis was performed to filter any patient summary for which the mean distance in UMAP space of its 5 nearest neighbors was greater than 2 standard deviations for the cancer type (Figure 2). The similarity between the clinical trial patients and standard of care patient summary embedding distributions was calculated using the maximum mean discrepancy (MMD) technique.

9. Data and code availability

Our retrospective DFCI datasets included patient protected health information (PHI) and therefore cannot be shared. Therefore, to facilitate dissemination of our method, we developed a synthetic version of the standard of care patient summary dataset. Llama-3.1-70B was prompted to generate synthetic clinical notes, pathology reports, imaging reports, and condensed medical records based on hypothetical patients with cancer. The synthetic clinical documents were used to train another version of TinyBertTagger, and the synthetic condensed medical records were summarized and used to train versions of TrialSpace and TrialChecker based on the subset of clinical trial spaces extracted from clinicaltrials.gov that were not included in the external trial spaces evaluation subset. Code and synthetic data are available at https://huggingface.co/ksg-dfci/MatchMiner-AI . Model weights based on the synthetic data are available at https://huggingface.co/ksg-dfci/TrialChecker . A simple search engine based on user-entered patient summaries for cancer trials extracted from clinicaltrials.gov is available at

https://huggingface.co/spaces/ksg-dfci/trial_search_alpha .

Results

Cohort

Our retrospective trial enrollment dataset included 16,139 enrollments for 13,425 patients onto 1534 clinical trials with 4074 extracted trial "spaces" since 2016. Our retrospective dataset of patients starting standard of care treatment included 86,042 treatment plans for 50,799 patients. Patient characteristics are listed in Table 1.

Information for 19,610 cancer trials listed as currently accruing on clinicaltrials.gov on October 22, 2024 was downloaded. We prompted Llama-3.1-70B to extract lists of clinical

'spaces' for each trial, yielding 38,140 total spaces. Of these, we restricted 37,932 spaces for 19,554 trials that were not included in our retrospective DFCI dataset. To reflect a realistic volume of open clinical trials at an academic cancer center for further analysis, we randomly sampled 500 of these trials, yielding 875 total spaces and 864 unique spaces.

Patient-centric use case

Evaluations for the patient-centric use case were performed using a 10% held out test subset of each cohort to reflect a realistic clinical volume of patients receiving active treatment at our center at any given time.

Pipeline performance in the retrospective DFCI trial enrollment dataset

In the test subset of DFCI patient summaries from retrospective enrollments, identifying the top 10 ranked candidate trial spaces using TrialSpace alone yielded a precision @ 10 of 0.72 and MAP @ 10 of 0.87. After the top ten trial spaces for each summary were further restricted to those predicted by TrialChecker to pass the "reasonable consideration" standard, the precision @ 10 was 0.89 and MAP @ 10 was 0.93. After incorporation of TrialChecker filtering, the median number of top ten ranked spaces still remaining was 8, with a mean of 7.5 (Table 2; Supplementary Figure 1).

Pipeline performance for non-trial enrollees and non-DFCI trials

When the test subset of DFCI patient summaries corresponding to initiation of standard of care treatment (n=9494) was used to query the sample of 864 unique spaces from 500 trials open for cancer per clinicaltrials.gov as of October 2024, TrialSpace alone yielded a precision of 0.73, with MAP @ 10 of 0.83. With addition of the TrialChecker filter, precision @ 10 was 0.87,

and MAP @ 10 was 0.91; the median number of results remaining per query was 8, with a mean of 7.5. (Table 2; Supplementary Figure 1).

Trial-centric use case

Pipeline performance in the retrospective DFCI trial enrollment dataset

When TrialSpace was used to rank the top twenty patient summaries for each trial space (n=4074) in our retrospective DFCI enrollment dataset, the precision @ 20 was 0.65 and MAP @ 20 was 0.83. After incorporation of TrialChecker filtering, precision @ 20 was 0.91 and MAP @ 20 was 0.93; the median number of results remaining was 16, with mean of 13.2 (Table 3; Supplementary Figure 2). This trial-centric evaluation did not restrict queryable patient summaries to those in the test set, since our training/validation/test split was performed at the patient level rather than the trial level, and an interpretable precision metric requires a realistic quantity of patients for evaluation.

Pipeline performance for non-trial enrollees and non-DFCI trials

When TrialSpace was used alone to rank the top twenty DFCI test set patient summaries corresponding to SOC treatments for each external trial space (n=864 spaces for 500 trials) in our clinicaltrials.gov sample, precision @ 20 was 0.74, and MAP @ 20 was 0.82. Incorporating TrialChecker yielded precision @ 20 of 0.87 and MAP @ 20 of 0.90. TrialChecker yielded a median of 18 patients per query, with a mean of 15.8 (Table 3; Supplementary Figure 2). Since the number of available patient summaries in the SOC dataset was considerably larger than the number in the retrospective trial dataset, queryable patient summaries were restricted to the 10% test subset for this evaluation.

Visualization of TrialSpace embeddings

An unsupervised UMAP plot was generated to illustrate how a lung cancer trial participant's patient summary (Figure 2a) was embedded and projected into two dimensions (Figure 2b). In this space, patients on standard of care and clinical trials co-located, and the maximum mean discrepancy (MMD) analysis between standard-of-care and clinical trial patient summaries indicated highly similar distributions (MMD=0.01, $p \le 0.0001$). Moreover, patient summaries naturally clustered by cancer type within the UMAP embedding (Figure 2b), as reflected by a high average cosine similarity within cancer types (0.79) compared to between cancer types (0.24). Focusing only on lung cancer clinical trial summaries and patient summaries further demonstrated the alignment between trials and patients (Figure 2e), emphasizing the model's ability to map related clinical entities closely in embedding space. The Llama check response text (Figure 2d) assessing the eligibility of the patient with lung cancer (Figure 2a) for the clinical trial NCT04644237 (Figure 2c) highlighted how Llama 3.1 70B was able to resolve and link ERBB2 and HER2 in the biomarker eligibility determination. The TrialChecker assessment was positive with a score 0.98.

Synthetic data for sharing

Performance of the versions of TrialSpace and TrialChecker re-trained on synthetic data to facilitate sharing is detailed in Supplemental Tables 2 and 3. Precision metrics for the synthetic data-trained TrialSpace were lower than those for the PHI-trained TrialSpace, but this gap narrowed when the synthetic data-trained TrialChecker was added to the pipeline, at the expense of returning fewer results per query. For example, for the patient-centric use case in the PHI-containing DFCI retrospective trial enrollment dataset, precision @ 10 was 0.72 and MAP @ 10 was 0.87 for TrialSpace alone, while precision @ 10 was 0.89 with MAP @ 10 of 0.93 for

TrialSpace + TrialChecker (Table 2). When the models were re-trained with synthetic data, precision @ 10 was 0.60 with MAP @ 10 of 0.74 for TrialSpace alone, with precision @ 10 of 0.85 and MAP @ 10 of 0.89 for TrialSpace + TrialChecker (Supplemental Table 2). The PHI-trained TrialSpace + TrialChecker returned a median of 8 with mean of 7.5 results per query (Table 2), while the synthetic data-trained TrialSpace+TrialChecker returned a median of 6 with mean of 5.9 results per query (Supplemental Table 2).

Discussion

This study describes the development and evaluation of the open-source MatchMiner-AI pipeline, which ranks cancer clinical trial options for patients and vice versa, based on core clinical criteria derived from unstructured EHR data and trial documentation.

This approach offers several strengths. The prompting strategy yields interpretable patient summaries focused on core clinical criteria based on a patient's entire longitudinal EHR text history, which is applicable not just to clinical trial matching but to clinical data abstraction generally. We focus on matching based on clinical "spaces" in the sense used in drug development, such as the "first-line advanced EGFR mutant non-small cell lung cancer space." Since we do not attempt to fully automate trial screening and determine whether a given patient meets each one of the many common eligibility criteria for trials in general, we facilitate understanding of the landscape of trial options available for patients with specific disease contexts. This avoids saddling our pipeline with a focus on boilerplate eligibility criteria, such as requirements about comorbidities, or brain metastases.

We also demonstrated generalizability of the pipeline to trials that were not open at our center and patients at our center who did not enroll in trials. Given the open-source nature of the models and requirement for minimal structured data for training and inference, any health

system could apply it to train custom versions of "TinyBertTagger" for information retrieval, "TrialSpace" for clinical trial matching, and "TrialChecker" for additional specificity. While we developed the pipeline for oncology, it could be easily modified to rank specific trials for other medical conditions based on key "space"-defining concepts for such diseases. In essence, this approach distills small, efficient models for information extraction, trial ranking, and eligibility classification from an LLM so that inference can be run rapidly at scale without querying the LLM directly.

Our pipeline also has limitations. Importantly, by design, it does not fully automate trial screening based on boilerplate eligibility criteria common to most trials. It does not replace the judgment of clinicians in weighing treatment options for patients or constitute an approved formal clinical decision support tool. An additional limitation is our reliance on LLM assessments of whether a given trial space was a "reasonable consideration" for a given patient to define labels for model training and evaluation. This was necessary in part because we had structured retrospective data describing the trials on which patients enrolled, but not on the clinical 'spaces' within those trials for which patients might have been eligible, or on trials for which patients might have been eligible but happened not to be those on which they enrolled. Manual review of all LLM "reasonable consideration" assessments generated for training and validation, which numbered in the hundreds of thousands, would have been prohibitive.

The "reasonable consideration" standard is inherently subjective, and different LLMs – as well as different oncologists – would likely provide different answers about whether a patient-trial pair meets this criterion. Our precision metric is also sensitive to the number of clinical trials and number of patients eligible for inclusion in a query. We focused on denominators of patients and open trials consistent with historical patterns at our center. However, if the pipeline were applied to query all open trials on clinicaltrials.gov or all patients in a multi-institutional health system, the precision would be higher, since the probability that top matches are clinically reasonable increases in proportion to the number of possible matches. Finally, although we evaluated the pipeline on trials that were not open at our center and hence were never seen in training, and for patients at our center who did not enroll in clinical trials, generalizability to patient histories derived from other institutions requires further research.

Our pipeline for deployment was trained on real retrospective EHR data containing PHI at our site, yielding models that cannot be shared publicly. To facilitate dissemination of this approach, we therefore developed versions for publication based on synthetic data. These yielded performance that was useful, though not as good as the PHI-trained models. Further work is needed to improve the quality of synthetic data available for clinical AI deployment.

In conclusion, we applied a large language model to distill an open pipeline for clinical phenotyping and cancer clinical trial matching. Future work will focus on improving pipeline performance and field-testing it with clinicians, registered nurses, and clinical trial investigators.

Acknowledgments

The authors acknowledge financial support from Meta Corp and the Nancy Lurie Marks Family Foundation.

References

- 1. Kehl KL, Arora NK, Schrag D, et al. Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer. *J Natl Cancer Inst*. 2014;106(10):1-9.
- 2. Jenei K, Haslam A, Olivier T, Miljkovíc M, Prasad V. What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015-2020). *BMJ Open*. 2022;12(10):e064458.
- Carlisle B, Kimmelman J, Ramsay T, MacKinnon N. Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials. *Clin Trials*. 2015;12(1):77-83.
- 4. Clinical trial solutions. Foundation Medicine. Accessed December 10, 2023. https://www.foundationmedicine.com/service/clinical-trial-solutions
- 5. Clinical trial matching. Tempus. August 20, 2020. Accessed December 10, 2023. https://www.tempus.com/oncology/clinical-trial-matching/
- 6. Leal health: Treatments. Choices. Hope. Leal Health. Accessed December 10, 2023. https://www.leal.health/
- 7. Carebox. Carebox connect. Carebox Connect. Accessed December 10, 2023. https://connect.careboxhealth.com/en-US
- 8. Ancora find cancer clinical trials. Ancora. Accessed December 10, 2023. https://www.ancora.ai/
- 9. Oncology clinical trial software. Inteliquet. March 23, 2022. Accessed December 10, 2023. https://inteliquet.com/
- Zhang X, Xiao C, Glass LM, Sun J. DeepEnroll: Patient-Trial Matching with Deep Embedding and Entailment Prediction. *arXiv [csAl]*. Published online January 22, 2020. http://arxiv.org/abs/2001.08179
- Gao J, Xiao C, Glass LM, Sun J. COMPOSE: Cross-Modal Pseudo-Siamese Network for Patient Trial Matching. *arXiv [csLG]*. Published online June 15, 2020. http://arxiv.org/abs/2006.08765
- 12. Das A, Thorbergosson L, Griogorenko A. Using Machine Learning to Recommend Oncology Clinical Trials. *Decisions*. Published online 2015. http://people.csail.mit.edu/dsontag/papers/das_etal_mlhc17.pdf
- 13. Peikos G, Symeonidis S, Kasela P, Pasi G. Utilizing ChatGPT to enhance clinical trial enrollment. *arXiv [csIR]*. Published online June 3, 2023. http://arxiv.org/abs/2306.02077
- Wong C, Zhang S, Gu Y, et al. Scaling clinical trial matching using large language models: A case study in oncology. Deshpande K, Fiterau M, Joshi S, et al., eds. *MLHC*. 2023;219:846-862.
- 15. Jin Q, Wang Z, Floudas CS, et al. Matching patients to clinical trials with large language models. *Nature Communications*. 2024;15(1):1-14.

- 16. Khoury NA, Shaik M, Wurmus R, Akalin A. Enhancing biomarker-based oncology trial matching using large language models. *bioRxiv*. Published online September 19, 2024. doi:10.1101/2024.09.13.612922
- 17. Yuan J, Tang R, Jiang X, Hu X. Large language models for healthcare data augmentation: An example on patient-trial matching. *AMIA Annu Symp Proc*. 2023;2023:1324-1333.
- 18. Rybinski M, Kusa W, Karimi S, Hanbury A. Learning to match patients to clinical trials using large language models. *J Biomed Inform*. 2024;159(104734):104734.
- 19. Gupta SK, Basu A, Nievas M, et al. PRISM: Patient Records Interpretation for Semantic Clinical Trial Matching using Large Language Models. *arXiv [csCL]*. Published online April 23, 2024. http://arxiv.org/abs/2404.15549
- 20. Wornow M, Lozano A, Dash D, Jindal J, Mahaffey KW, Shah NH. Zero-Shot Clinical Trial Patient Matching with LLMs. *arXiv [csCL]*. Published online February 5, 2024. http://arxiv.org/abs/2402.05125
- 21. Park JJH, Siden E, Zoratti MJ, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. *Trials*. 2019;20(1):572.
- 22. Dubey A, Jauhri A, Pandey A, et al. The Llama 3 herd of models. *arXiv [csAl]*. Published online July 31, 2024. Accessed September 16, 2024. http://arxiv.org/abs/2407.21783
- 23. Orechia J, Pathak A, Shi Y, et al. OncDRS: An integrative clinical and genomic data platform for enabling translational research and precision medicine. *Applied & Translational Genomics*. 2015;6:18-25.
- 24. Lewis P, Perez E, Piktus A, et al. Retrieval-Augmented Generation for Knowledge-Intensive NLP Tasks. *arXiv [csCL]*. Published online May 22, 2020. http://arxiv.org/abs/2005.11401
- 25. Jiao X, Yin Y, Shang L, et al. TinyBERT: Distilling BERT for natural language understanding. *arXiv* [csCL]. Published online September 23, 2019. http://arxiv.org/abs/1909.10351
- 26. dunzhang/stella_en_1.5B_v5 · Hugging Face. Accessed October 20, 2024. https://huggingface.co/dunzhang/stella_en_1.5B_v5
- 27. Henderson M, Al-Rfou R, Strope B, et al. Efficient Natural Language Response Suggestion for Smart Reply. *arXiv [csCL]*. Published online May 1, 2017. http://arxiv.org/abs/1705.00652
- McInnes L, Healy J, Melville J. UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction. *arXiv [statML]*. Published online February 9, 2018. http://arxiv.org/abs/1802.03426
- 29. Reimers N, Gurevych I. Sentence-BERT: Sentence embeddings using Siamese BERT-networks. *arXiv [csCL]*. Published online August 27, 2019. http://arxiv.org/abs/1908.10084
- 30. Liu Y, Ott M, Goyal N, et al. RoBERTa: A Robustly Optimized BERT Pretraining Approach. *arXiv* [csCL]. Published online July 26, 2019. http://arxiv.org/abs/1907.11692
- 31. Wolf T, Debut L, Sanh V, et al. HuggingFace's Transformers: State-of-the-art Natural

Page 22

Language Processing. Published online October 8, 2019. http://arxiv.org/abs/1910.03771

32. Kundra R, Zhang H, Sheridan R, et al. OncoTree: A cancer classification system for precision oncology. *JCO Clin Cancer Inform*. 2021;5(5):221-230.

	Table	1:	Patient	characteristics
--	-------	----	---------	-----------------

	DFCI Dataset			
Characteristic	Trial Enrolled	SOC		
	N (patients) = 13,086 ¹	N (patients) = 50,799 ¹		
Sex				
Female	7,174 (55%)	28,135 (55%)		
Male	5,911 (45%)	22,662 (45%)		
Unknown	1 (<0.1%)	2 (<0.1%)		
Age at first Treatment Start				
<50	2,451 (19%)	8,932 (18%)		
50-59	3,287 (25%)	10,614 (21%)		
60-69	4,365 (33%)	14,932 (29%)		
70-79	2,583 (20%)	11,970 (24%)		
80+	400 (3.1%)	4,351 (8.6%)		
Year of Treatment Start				
2016	2,367 (18%)	8,766 (17%)		
2017	2,319 (18%)	6,748 (13%)		
2018	2,307 (18%)	6,817 (13%)		
2019	2,110 (16%)	7,160 (14%)		
2020	1,328 (10%)	6,824 (13%)		
2021	1,248 (9.5%)	7,160 (14%)		
2022	933 (7.1%)	7,324 (14%)		
2023	439 (3.4%)	0 (0%)		
2024	35 (0.3%)	0 (0%)		
Race per medical record				
White	11,682 (89%)	43,626 (86%)		
Black Or African American	405 (3.1%)	2,148 (4.2%)		
Asian	460 (3.5%)	2,059 (4.1%)		
Other/multiple/unknown	539 (4.1%)	2,966 (5.8%)		
Ethnicity per medical record				
Hispanic	411 (3.1%)	2,162 (4.3%)		
Non-Hispanic	12,675 (97%)	48,637 (96%)		
Disease center				
Other	-	17,153 (34%)		
Breast	-	7,880 (16%)		
Lung	-	5,912 (12%)		
Lymphoma	-	4,493 (8.8%)		

Leukemia	-	3,150 (6.2%)
Colorectal	-	3,126 (6.2%)
Pancreas	-	2,408 (4.7%)
Myeloma	-	2,005 (3.9%)
Prostate	-	1,789 (3.5%)
Glioma	-	1,624 (3.2%)
Urothelial	-	1,259 (2.5%)

1 n (%) Table 2: Performance metrics for the patient-centric use case (finding up to 10 trial spaces for individual patient summary queries)

Metric	Retrospective DFCI trial enrollment dataset (Patient test split; n=1576 patient summaries queried)*		DFCI standard-of-care treatment start and external trials dataset (Patient test split; n=9494 patient summaries queried)	
	TrialSpace alone	TrialSpace + TrialChecker	TrialSpace alone	TrialSpace + TrialChecker
Precision @ 10	0.72	0.89	0.73	0.87
MAP @ 10	0.87	0.93	0.83	0.91
Median results returned per query (N)	10	8	10	8
Mean results returned per query (N)	10	7.5	10	7.5

Legend to Table 2: Metrics evaluated using Llama-3.1-70B's response to the "reasonable consideration" prompt as the gold standard. The top 10 ranked trial spaces per the TrialSpace model were evaluated for each patient summary.

* In the retrospective DFCI trial enrollment dataset, spaces were ranked only if they corresponded to trials that were open at the time of the patient's trial enrollment.

Metric	Retrospective DFCI trial enrollment dataset (n=4074 trial spaces queried)*		DFCI standard-of-care treatment start and external trials dataset (n=864 trial spaces queried)**	
	TrialSpace alone	TrialSpace + TrialChecker	TrialSpace alone	TrialSpace + TrialChecker
Precision @ 20	0.65	0.91	0.74	0.87
MAP @ 20	0.83	0.93	0.82	0.90
Median results returned (N)	20	16	20	18
Mean results returned (N)	20	13.2	20	15.8

Table 3: Performance metrics for the trial-centric use case (finding up to 20 patients for individual trial space queries)

Legend to Table 3: Metrics evaluated using Llama-3.1-70B's response to the "reasonable consideration" prompt as the gold standard. The top 20 ranked patient summaries per the TrialSpace model were evaluated for each trial space.

* Metrics for the retrospective DFCI trial enrollment dataset include patients in training, validation, and test splits, since splitting was performed at the patient level and not the trial level. Patients were ranked only if their trial enrollment dates occurred while a queried trial space corresponded to a trial that was open at that time.

** Metrics for the standard of care treatment start dataset include patients in the test split only, to simulate realistic clinical volume at any given time.





Figure 2: TrialSpace embedding visualization



Legend to Figure 2: An overview of the MatchMiner-AI trial matching process. (a) has an example lung cancer patient summary who participated in a clinical trial. (b) is a UMAP of the text embedding projected into 2-dimensions, patient summaries are colored by the organ of their primary cancer type according to the OncoTree ontology. Summaries from the retrospective trial enrollment dataset and from the standard of care treatment dataset were both included in this figure, as indicated by the shape of the marker. (c) is the AI generated clinical trial summary for the patient in (a). (d) is the response from the Llama check to determine if the patient (a) is eligible for clinical trial (c). (e) is a UMAP of all lung patients and trials, with the green arrows indicating the 10 top ranked trials by cosine distance, the blue cross indicates the trial the patient actually enrolled on.

Supplementary Figure 1: TrialChecker model performance for patient-centric (spaces-for-patients) task



Legend to Supplementary Figure 1: Area under the receiver operating characteristic curve, AUROC. Area under precision-recall curve, AUPRC. Metrics treated the Llama-3.1-70B "reasonable consideration" check as a gold standard label. Performance measured in the test subset of each cohort.

Supplementary Figure 2: TrialChecker model performance for trial-centric (patients-for-spaces) task



Legend to Supplementary Figure 2: Area under the receiver operating characteristic curve, AUROC. Area under precision-recall curve, AUPRC. Metrics treated the Llama-3.1-70B "reasonable consideration" check as a gold standard label.

Supplementary Table 1: Llama-3.1-70B prompts

Task	Source data	Prompt
Trial space extraction	Trial eligibility criteria from clinicaltrials.gov	messages = [{'role':'system', 'content': """You are an expert clinical oncologist with an encyclopedic knowledge of cancer and its treatments. Your job is to review a clinical trial document and extract a list of structured clinical spaces that are eligible for that trial. A clinical space is defined as a unique combination of cancer primary site, histology, which treatments a patient must have received, which treatments a patient must not have received, cancer burden (eg presence of metastatic disease), and tumor biomarkers (such as germline or somatic gene mutations or alterations, or protein expression on tumor) that a patient must have or must not have; that renders a patient eligible for the trial.
		Trials often specify that a particular treatment is excluded only if it was given within a short period of time, for example 14 days, one month, etc , prior to trial start. Do not include this type of time-specific treatment eligibility criteria in your output at all.
		Some trials have only one space, while others have several. Do not output a space that contains multiple cancer types and/or histologies. Instead, generate separate spaces for each cancer type/histology combination.
		For biomarkers, if the trial specifies whether the biomarker will be assessed during screening, note that.
		Spell out cancer types; do not abbreviate them. For example, write "non-small cell lung cancer" rather than "NSCLC".
		Structure your output like this, as a list of spaces, with spaces separated by newlines, as below:
		1. Cancer type allowed: <cancer_type_allowed>. Histology allowed: <histology_allowed>. Cancer burden allowed: <cancer_burden_allowed>. Prior treatment required: <prior_treatments_requred>. Prior treatment excluded: <prior_treatments_excluded>. Biomarkers required: <biomarkers_required>. Biomarkers excluded: <biomarkers_excluded>.</biomarkers_excluded></biomarkers_required></prior_treatments_excluded></prior_treatments_requred></cancer_burden_allowed></histology_allowed></cancer_type_allowed>

		2. Cancer type allowed: <cancer_type_allowed>, etc.</cancer_type_allowed>
		If a particular concept is not mentioned in the trial text, do not include it in your definition of trial space(s)."""}, {'role':'user', 'content': "Here is a clinical trial document: \n" + trial + "\n" + """Now, generate your list of the trial space(s), formatted as above. Do not provide any introductory, explanatory, concluding, or disclaimer text.
		Reminder: Treatment history is an important component of trial space definitions, but treatment history requirements that are described as applying only in a given period of time prior to trial treatment MUST BE IGNORED."""}]
Patient summarization	Historical unstructured EHR documents for the patient	 messages = [{'role':'system', 'content': """You are an experienced clinical oncology history summarization bot. Your job is to construct a summary of the cancer history for a patient based on an excerpt of the patient's electronic health record. The text in the excerpt is provided in chronological order. Document the cancer type/primary site (eg breast cancer, lung cancer, etc); histology (eg adenocarcinoma, squamous carcinoma, etc); current extent (localized, advanced, metastatic, etc); biomarkers (genomic results, protein expression, etc); and treatment history (surgery, radiation, chemotherapy/targeted therapy/immunotherapy, etc, including start and stop dates and best response if known). Do not consider localized basal cell or squamous carcinomas of the skin, or colon polyps, to be cancers for your purposes. Do not include the patient's name, but do include relevant dates whenever documented, including dates of diagnosis and start/stop dates of each treatment. If a patient has a history of more than one cancer, document the cancers one at a time."""},

		{'role':'user', 'content': "The excerpt is:\n" + the_patient + """Now, write your summary. Do not add preceding text before the abstraction, and do not add notes or commentary afterwards. This will not be used for clinical care, so do not write any disclaimers or cautionary notes."""}]
"Reasonable consideration" patient-space match check	Llama-generated patient summaries and trial spaces	messages = [{'role':'system', 'content': """You are a brilliant oncologist with encyclopedic knowledge about cancer and its treatment. Your job is to evaluate whether a given clinical trial is a reasonable consideration for a patient, given a clinical trial summary and a patient summary.\n"""},
		{'role':'user', 'content': "Here is a summary of the clinical trial:\n" + trial_summary + "\nHere is a summary of the patient:\n" + patient_summary + """Base your judgment on whether the patient generally fits the cancer type(s), cancer burden, prior treatment(s), and biomarker criteria specified for the trial.
		You do not have to determine if the patient is actually eligible; instead please just evaluate whether it is reasonable for the trial to be considered further by the patient's oncologist.
		Some trials have biomarker requirements that are not assessed until formal eligibility screening begins; please ignore these requirements.
		Reason step by step, then answer the question "Is this trial a reasonable consideration for this patient?" with a one-word "Yes!" or "No!" answer.
		Make sure to include the exclamation point in your final one-word answer."""}]
Extraction of Cancer type per OncoTree	Llama-generated patient summaries and trial	messages = [{'role': 'system', 'content': """Determine the organ of allowed cancer type in the provided clinical description. Follow these rules strictly:
	50000	1. Use only the organ names listed below to assign the organ.
		2. If the text allows for any solid tumor output "Solid tumor"
		3. If cancer does not have a well defined primary organ output "None"

	4. If cancer can appear in multiple primary organs output "None"
	5. If multiple cancers are listed output "Multiple"
	5. Output only the assigned organ as a python string, "Solid tumor", "Multiple" or "None" No additional text or explanation is needed.
	Here is the clinical trial text to parse:
	{txt}
	Below is the list of organs you can assign:
	Adrenal Gland, Ampulla of Vater, Biliary Tract, Bladder/Urinary Tract, Bone, Bowel, Breast, Cervix, CNS/Brain, Esophagus/Stomach, Eye, Head and Neck, Kidney, Liver, Lung, Lymphoid, Myeloid, Ovary/Fallopian Tube, Pancreas, Penis, Peripheral Nervous System, Peritoneum, Pleura, Prostate, Skin, Soft Tissue, Testis, Thymus, Thyroid, Uterus, Vulva/Vagina
None	messages = [
	{'role':'system', 'content': """Your job is to generate synthetic oncologist clinical progress notes for hypothetical patients with cancer.
	You know all there is to know about cancer and its treatments, so be detailed.
	"""},
	{'role':'user', 'content': """Imagine a patient with cancer.
	The cancer type is""" + cancer_types[i] + "." + """
	None

		The patient might have any stage of disease. Use everything you know about cancer, including biomarkers, epidemiology, and heterogeneity in disease presentations. The note might correspond to any point along the disease trajectory, from
		initial diagnosis to curative intent treatment to palliative intent treatment.
		The note should include a chief complaint, oncologic history including prior treatments, past medical history/comorbidities, current subjective clinical status and physical exam including vital signs and ECOG performance status, laboratory values, radiology excerpts, and an assessment and plan.
		The note should be approximately two pages long. It will not be used for clinical care, so do not include disclaimers."""}
]
Generation of synthetic imaging	None	messages = [
reports		{'role':'system', 'content': """Your job is to generate synthetic imaging reports for hypothetical patients with cancer.
		You know all there is to know about cancer and its treatments, so be detailed.
		"""},
		{'role':'user', 'content': """Imagine a patient with cancer.
		The cancer type is """ + cancer_types[i] + "." + """

Generation of synthetic pathology reports

		Then, generate a very detailed pathology report that might have been written about a specimen collected from the patient. The patient might have any stage of disease. Use everything you know about cancer, including biomarkers, epidemiology, and heterogeneity in disease presentations. The report might be from a cytology specimen, anatomic pathology specimen, genomic sequencing analysis, bone marrow biopsy, flow cytometry, SPEP, etc. The report should not include any treatment recommendations. The pathology report should be approximately a full page long."""}
Generation of synthetic patient histories	None	<pre>messages = [{'role':'system', 'content': """Your job is to generate synthetic clinical histories for hypothetical patients with cancer. You know all there is to know about cancer and its treatments, so be detailed. The histories should be presented in chronological order as a sequence of events. Each event should begin with a date, and should then include some new development, such as a diagnosis, treatment, adverse event, progression, response to therapy, biomarker ascertainment, symptom burden, recurrence events, and so on. """], {'role':'user', 'content': """Imagine a patient with cancer. The cancer type is """ + cancer_types[i] + """.</pre>

Then, generate a very detailed synthetic clinical history for the patient. The patient might have any stage of disease. Use everything you know about cancer, including epidemiology, treatment options, outcomes, and heterogeneity in disease trajectories.
Do not mention transitions to hospice or death events.
Do not start with any demographics; just launch into the chronological history. Phrase it in the past tense. Dates should be in mm/dd/yyyy format. Output should be plain text, not Markdown.
The history should be approximately two pages long."""}
]

Supplemental Table 2: Performance metrics for the patient-centric use case (finding up to 10 trial spaces for individual patient summary queries) using model versions trained on synthetic data

Metric	Retrospective DFCI trial enrollment dataset (Patient validation split; n=1582 patient summaries queried)*		DFCI standard-of-care treatment start and external trials dataset (Patient validation split; n=9515 patient summaries queried)	
	TrialSpace alone	TrialSpace + TrialChecker	TrialSpace alone	TrialSpace + TrialChecker
Precision @ 10	0.60	0.85	0.62	0.85
MAP @ 10	0.74	0.89	0.75	0.90
Median results returned per query (N)	10	6	10	6
Mean results returned per query (N)	10	5.9	10	6.0

Legend to Table 2: Metrics evaluated using Llama-3.1-70B's response to the "reasonable consideration" prompt as the gold standard. The top 10 ranked trial spaces per the TrialSpace model were evaluated for each patient summary.

* In the retrospective DFCI trial enrollment dataset, spaces were ranked only if they corresponded to trials that were open at the time of the patient's trial enrollment.

Supplementary Table 3: Performance metrics for the trial-centric use case (finding up to 20 patients for individual trial space queries) using model versions trained on synthetic data

Metric	Retrospective DFCI trial enrollment dataset (n=4074 trial spaces queried)*		DFCI standard-of-care treatment start and external trials dataset (n=864 trial spaces queried)**	
	TrialSpace alone	TrialSpace + TrialChecker	TrialSpace alone	TrialSpace + TrialChecker
Precision @ 20	0.56	0.87	0.65	0.86
MAP @ 20	0.72	0.89	0.72	0.88
Median results returned (N)	20	12	20	16
Mean results returned (N)	20	11.2	20	13.6

Legend to Table 3: Metrics evaluated using Llama-3.1-70B's response to the "reasonable consideration" prompt as the gold standard. The top 20 ranked patient summaries per the TrialSpace model were evaluated for each trial space.

* Metrics for the retrospective DFCI trial enrollment dataset include patients in training, validation, and test splits, since splitting was performed at the patient level and not the trial level. Patients were ranked only if their trial enrollment dates occurred while a queried trial space corresponded to a trial that was open at that time.

** Metrics for the standard of care treatment start dataset include patients in the validation split only, to simulate realistic clinical volume at any given time.